Hepatocellular Carcinoma
Conditions
Keywords
Hepatocellular carcinoma, Hepatitis B
Brief summary
To evaluate the safety, tolerability and efficacy of autologous γδT cells in the treatment of advanced hepatitis B-related hepatocellular carcinoma.
Detailed description
This is a single-centre, non-randomised, open label, no control, prospective clinical trial. The study will include the following sequential phases: sign informed consent, γδT cells pre-culture, fresh biopsy and screening, apheresis, γδT cells preparation, treatment and follow-up. The study will evaluate the safety, tolerability and efficacy of autologous γδT cells in patients with advanced hepatitis B related hepatocellular carcinoma (HCC) which are refractory to current treatment. Stage I comprising a safety cohort of patients to identify a safe dose, Stage II comprising an expanded patient group for response signal identification, Stage III to confirm efficacy and safety.
Interventions
BIOLOGICALautologous γδT cells
Cells will be extracted by apheresis, followed by expanding and activating. The autologous γδT cells product will be adoptive transferred.
Sponsors
Chinese Academy of Medical Sciences
Beijing 302 Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
1. Patients should sign informed consent form voluntarily and comply with the requirements of this study. 2. Gender unlimited, age 18 to 70 years old. 3. Hepatocellular carcinoma histopathology proven by liver fresh biopsy. 4. According to the 2018 edition of the EASL guidelines for primary liver cancer, patients were diagnosed with advanced HBV-related hepatocellular carcinoma (BCLC stage B and C) by pathology and imaging; all patients required antiviral therapy with nucleoside analogues; other treatments (e.g. interventional therapy) at least 2 weeks prior to γδT cell infusion; patients can take the first- or second-line targeted drugs recommended by the guidelines, such as lenvatinib or sorafenib. 5. Liver function: Child-Pugh class A/B (5-9), Eastern Cooperative Oncology Group (ECOG) Performance status 0-2. 6. Expected survival ≥ 6 months. 7. Male and female of reproductive potential must agree to use birth control during the study and for at least 30 days post study.
Exclusion criteria
1. Combine other viral liver diseases or other liver disease patients. 2. Acute infection, gastrointestinal bleeding, etc. occurred within 30 days before screening. 3. Pregnant or lactating women; patients after organ transplantation; patients with severe autoimmune diseases; patients with uncontrolled infectious diseases. 4. Dysfunction of major organs; patient white blood cell count \<1.0×10e9/L, platelet count \<60×10e9/L, hemoglobin \<86g/L, prothrombin time (INR) \>2.3, or prolonged clotting time \>6 seconds, serum albumin \<28g/L, total bilirubin \>51mmol/L, ALT/AST \>5 times the upper limit of normal, creatinine \>1.5 times the upper limit of normal. 5. Combined with other serious organic diseases, mental illnesses, including any uncontrolled clinically significant systemic diseases such as urinary, circulatory, respiratory, neurological, psychiatric, digestive, endocrine and immune diseases. 6. Allergic constitution, history of allergies to blood products, known to be allergic to test substances. 7. Immunosuppressive or systemic cytotoxic drugs may require within six months prior to screening or during treatment; 6 months prior to screening accepted other cell therapies including NK, CIK, DC, CTL and stem cell therapy etc.; immunotherapy such as PD-1 and PD-L1 antibodies. 8. Patients currently participating in other clinical trials who may violate this treatment plan and observations. 9. Those who are unable or unwilling to provide informed consent or who are unable to comply with the research requirements. 10. Any situation that investigators believe the risk of the subjects is increased or results of the trial are disturbed: patients with any serious acute or chronic physical or mental illness, or laboratory abnormalities.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of adverse events (AEs) and serious adverse events (SAEs) | 14 months | Incidence of adverse events (AEs) and serious adverse events (SAEs) of each patient will be recorded and analyzed. |
| Overall survival (OS) | 14 months | Overall survival is defined as the time from the day in which the patient is enrolled to the date on which the patient dies for any cause. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Objective Response Rate (ORR) | 14 months | The objective response rate (ORR) is defined as the proportion of patients who achieve radiographic partial or complete response (PR or CR) according to the response evaluation criteria in solid tumors (RECIST) guideline. |
| Patients-based Quality of Life Evaluation | 14 months | According to the European Organization for Research and Treatment of Cancer (EORTC) quality of life of the core scale criteria QLQ-C30 to evaluate and compare patients life quality before and after treatment. |
Countries
China
Contacts
Primary ContactYuanyuan Li, Dr
Outcome results
None listed